<DOC>
	<DOCNO>NCT00559741</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , cetuximab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Drugs use chemotherapy , irinotecan , fluorouracil , leucovorin , work different way stop growth tumor cell , either kill cell stop divide . Giving cetuximab together combination chemotherapy may kill tumor cell . PURPOSE : This phase II trial study well give cetuximab together combination chemotherapy work treat patient advanced metastatic colorectal cancer .</brief_summary>
	<brief_title>Cetuximab Combination Chemotherapy Treating Patients With Advanced Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Improve hematologic gastrointestinal tolerance cetuximab irinotecan hydrochloride , fluorouracil , leucovorin calcium ( FOLFIRI ) patient advance metastatic colorectal cancer . Secondary - Increase effectiveness regimen intensify treatment . - Specify constitutional genetic genomic tumor parameter could interfere predict toxicity and/or antitumor efficacy regimen . - Assess time progression . OUTLINE : This multicenter study . Patients receive irinotecan hydrochloride IV 90 minute , leucovorin calcium IV 2 hour , cetuximab IV 1-2 hour day 1 . Patients also receive fluorouracil IV continuously 46 hour day 1 2 . Treatment repeat every 2 week absence disease progression unacceptable toxicity . Pharmacokinetic pharmacogenetic study also conduct .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm colorectal cancer Advanced metastatic disease Scheduled receive first secondline therapy metastatic disease No cerebral metastasis symptomatic uncontrolled meningeal disease PATIENT CHARACTERISTICS : WHO performance status 02 ANC ≥ 2,000/mm^3 Platelet count ≥ 100,000/mm^3 Total bilirubin ≤ 2 time upper limit normal ( ULN ) AST ALT ≤ 3 time ULN Alkaline phosphatase ≤ 5 time ULN Not pregnant nursing Fertile patient must use effective contraception No intestinal blockage No complete dihydropyrimidine dehydrogenase deficiency No chronic inflammatory disease colon No cancer except nonmelanoma skin cancer curatively treat carcinoma cervix breast No severe condition , condition likely worsen , include follow : Unstable heart disease Myocardial infarction within past 6 month Active uncontrolled infection No contraindication atropine PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered prior anticancer therapy More 4 week since prior concurrent investigational therapy Prior adjuvant chemotherapy allow No prior fluorouracil irinotecan hydrochloride No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
</DOC>